Hancock Jaffe Announces Objectives for Upcoming CoreoGraft Study

Tailwinds' Take: Texas Heart is a renowned leader in this space and hearing the results of this trial in April could be a major...

Dr. Marc H. Glickman to Present at 6th Israeli Vascular Access Conference

Tailwinds' Take: good detail about the timelines for VenoValve and CoreoGraft as CEO Berman is methodically moving HJLI down approval pathlines on both products....

Hancock Jaffe Announces End Points for First-in-Human VenoValve Study

Tailwinds' Take: this is just another indicator that Hancock Jaffe is successfully moving forward down the clinical pathway. We believe that a positive outcome...

Tailwinds Top 8 Surprises for 2019

Every year for the past 36 years, Byron Wien has put out a list of “Top 10 Surprises” for the...

CEO Interview: Rob Berman of Hancock Jaffe

Since taking over the CEO role at Hancock Jaffe on April 1, Rob Berman has been very busy. In addition to taking...

Hancock Jaffe Receives Approval for First-in-Human VenoValve Study

Tailwinds' Take: this long awaited news is a key milestone for HJLI as they will have two important studies kicking off in...

Hancock Jaffe Announces January CoreoGraft Study at the Texas Heart Institute

Tailwinds' Take: There are currently no approved alternatives to vein harvesting and this study is the last step before applying to the FDA to...

What To Put In Your Stockings: December Preview

This weekend we'll be hanging our stockings on the mantel. Come Christmas morning, they'll be lying on the floor, overflowing with presents. At least,...

Hancock Jaffe Updates Status of Application to INVIMA for First-In-Human VenoValve Trial in Colombia

Tailwinds' Take: making progress towards first-in-man trials, which dates will be announced in December; we expect an early Q1 2019 launch of the trial....

Hancock Jaffe Appoints Chris Sarner as Vice President of Regulatory Affairs and Quality Assurance

IRVINE, Calif., Nov. 13, 2018 (GLOBE NEWSWIRE) -- Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a company specializing in medical devices that restore cardiac...

Hancock Jaffe Shareholder Update Letter

Dear Hancock Jaffe Shareholders: Since joining Hancock Jaffe in April of 2018, this is the first occasion for me to address all of our shareholders...

October Review, Earnings Preview

October has a reputation for being a bad month to own stocks. For the current generation of investors, this reputation was earned primarily from...

Texas Heart Takes To The CoreoGraft™

This week Hancock Jaffe Laboratories (HJLI) announced a partnership with the Texas Heart Insitute, a world-renowned leader in cardiovascular disease. This partnership, which is...

Hancock Jaffe Enters into Sponsored Research Agreement for CoreoGraft with World-Renowned Texas Heart Institute

Tailwinds' Take: this is great news for their second product, the CoreoGraft. Texas Heart is a world class partner and the end market is...

Hancock Jaffe Appoints Three New Independent Directors

Tailwinds' Take: this is a great endorsement of the products and end markets that HJLI is targeting. The background of each new member is...

Hancock Jaffe Laboratories to Present at The MicroCap Conference on October 2, 2018 in...

IRVINE, Calif., Sept. 28, 2018 (GLOBE NEWSWIRE) -- Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a company specializing in medical devices that restore cardiac...

Hancock Jaffe Submits Application to INVIMA for First-In-Human VenoValve Trial in Colombia

Tailwinds' Take: another step towards being the only FDA approved product for CVI, a multi-billion dollar indication. We believe that the likelihood of this...

New Study Confirms Significant Potential U.S. Market for Hancock Jaffe’s VenoValve

Tailwinds' Take: The VenoValve is progressing towards FDA approval. Once approved, the market size is huge. HJLI is significantly undervalued based on this research. IRVINE,...

Hancock Jaffe Laboratories’ VenoValve Featured in Journal of Vascular Surgery Venous and Lymphatic Disorders...

IRVINE, Calif., Sept. 12, 2018 (GLOBE NEWSWIRE) -- Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a company specializing in medical devices that restore cardiac...

Counting Down To The VenoValve

With a market cap hovering around $25M, Hancock Jaffe Laboratories stock is severely discounting the success of any of its three products that are...
DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.